Clinical Significance of Differences in Bioavailability of Medroxyprogesterone Acetate Preparations
KeywordsMetastatic Breast Cancer Advanced Breast Cancer Medroxyprogesterone Acetate Cancer Treatment Report Cuna
Unable to display preview. Download preview PDF.
- Gupta C, Osterman J, Santen R, Bardin CW. In vitro metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women. Journal of Clinical Endocrinology and Metabolism 48: 816–820, 1979PubMedCrossRefGoogle Scholar
- Hedley DW, Christie M, Weatherby RP, Caterson ID. Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function and tumour response in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology 14: 112–115, 1985PubMedCrossRefGoogle Scholar
- Mould GP, Read J, Bye A. A comparison of the HPLC and RIA measurement of medroxyprogesterone acetate. Journal of Pharmaceutical and Biomedical Analysis, in press, 1988Google Scholar
- Sturm G, Schulz KD. MPA assays: measurement of plasma MPA levels in high-dose MPA-treated patients. In Pellegrini et al. (Eds) Role of medroxyprogesterone in endocrine-related tumours, Vol. 3, pp. 23–42, Raven Press, New York, 1984Google Scholar
© ADIS Press Limited 1989